<DOC>
	<DOCNO>NCT00260065</DOCNO>
	<brief_summary>The purpose study determine overall response rate patient myelodysplastic syndrome ( MDS ) give daily dose schedule decitabine .</brief_summary>
	<brief_title>A Study Decitabine Given Adults With Advanced-Stage Myelodysplastic Syndromes</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>1 . Must sign Institutional Review Board ( IRB ) approve informed consent form . 2 . Must 18 year age old . 3 . Must diagnosis MDS fitting recognize FrenchAmericanBritish ( FAB ) classification International Prognostic Scoring System ( IPSS ) great equal 0.5 determine Complete Blood Count ( CBC ) , bone marrow assessment , cytogenetics within 28 day receive study drug . If FAB classification Refractory anemia ( RA ) Refractory anemia ring sideroblast ( RARS ) , must red cell transfusion dependent , define needing red cell frequently every 4 week . 4 . If receive erythropoietin ( Procrit ) , must stable dose least 8 week first dose study drug . 5 . If receive darbepoetin ( Aranesp ) , must stable dose least 12 week first dose study drug . 1 . Must diagnosis Acute Myeloid Leukemia ( AML ) progressive malignant disease . 2 . Must receive investigational agent within 30 day precede first dose study drug . 3 . Must uncontrolled cardiac disease uncontrolled congestive heart failure . 4 . Must active viral bacterial infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>Decitabine</keyword>
	<keyword>Dacogen</keyword>
	<keyword>MGI Pharma</keyword>
</DOC>